LAMLIQUE
AZURITY · LAMOTRIGINE HEMIFUMARATE
Open FDA's page for this record- Application number
- NDA221109
- Sponsor name
- AZURITY
- Submissions
- Submission type
- ORIG
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20260925
- Review priority
- STANDARD
- Submission class code
- TYPE 2
- Submission class code description
- Type 2 - New Active Ingredient
- Application docs
- ID
- 87317
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/221109Orig1s000ltr.pdf
- Date
- 20260929
- Type
- Letter
- ID
- 87354
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/221109Orig1s000lbl.pdf
- Date
- 20261006
- Type
- Label
- Products
- Product number
- 001
- Reference drug
- Yes
- Brand name
- LAMLIQUE
- Reference standard
- Yes
- Dosage form
- SUSPENSION
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- LAMOTRIGINE HEMIFUMARATE
- Strength
- EQ 5MG BASE/ML
- Product number
- 002
- Reference drug
- Yes
- Brand name
- LAMLIQUE
- Reference standard
- Yes
- Dosage form
- SUSPENSION
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- LAMOTRIGINE HEMIFUMARATE
- Strength
- EQ 25MG BASE/ML
